H. Ranolazine
Ranolazine is an investigation treatment for angina. The drug is not Beta blocker, calcium antagonists or nitrate. Clarke et al. indicate that the drug appears to shift adenosine triphosphate production away from fatty acid oxidation in favor of more oxygen efficient carbohydrate oxidation. In a small clinical trialin patients with chronic angina the drug at a dose 500–1000 mg twice daily was well-tolerated and increased exercise performance without significant decrease in blood pressure or increase in heart rate. The drug did not alter survival in the one year follow up. The 1500-mg, twice daily dosing caused dizziness and nausea, ischemia, and constipation and rarely syncope. The drug should not be used in patients administered other agents that increase the QT interval.

Страницы: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22